Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel immune medicine for treating solid tumors

A technology for immune drugs and tumors, applied in anti-tumor drugs, drug combinations, drug delivery, etc., can solve problems such as high incidence of tumors, endangering the health of the general public, and no breakthroughs in chemotherapy

Active Publication Date: 2020-10-30
王磊 +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, the incidence of cancer is high, which seriously endangers the health of the general public. It is usually characterized by a high recurrence rate and causes a huge economic burden on the society.
At present, surgery is still the main treatment for tumors, but radiotherapy and chemotherapy have not made breakthroughs in the treatment of tumors, and the prognosis of stage III and stage IV tumors is still not optimistic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel immune medicine for treating solid tumors
  • Novel immune medicine for treating solid tumors
  • Novel immune medicine for treating solid tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] This embodiment provides an immunomedicine for treating solid tumors and a preparation method thereof.

[0057] 1. The immune drugs are type B drugs, including:

[0058] The viral expression vector pLVX-IRES-ZsGreen1 (donated by Beijing Li Keli Laboratory) that simultaneously expresses the Fut1 gene and the B blood group gene contains the nucleotide sequence SEQ ID NO.4, which includes the Fut1 gene, B blood type gene and connection sequence T2A;

[0059] The viral expression vector can express the amino acid sequence shown in SEQ ID NO.2;

[0060] 2. The preparation method of the immunomedicine is as follows:

[0061] (1) Synthetic nucleotide sequence SEQ ID NO.4;

[0062] (2) if figure 1 As shown, insert SEQ ID NO.4 into the pLVX-IRES-ZsGreen1 vector, and then package the therapeutic virus in 293T cells to obtain the new immune drug;

Embodiment 2

[0064] This embodiment provides an immunomedicine for treating solid tumors and a preparation method thereof.

[0065] 1. The immune drugs are type A drugs, including:

[0066] A virus expression vector expressing Fut1 gene and A blood group gene simultaneously, said virus expression vector comprising nucleotide sequence SEQ ID NO.3, which includes Fut1 gene, A blood group gene and connection sequence T2A; the virus expression vector can express SEQ ID NO.3 The amino acid sequence shown in ID NO.1;

[0067] 2. The preparation method of the immunomedicine is as follows:

[0068] (1) Synthetic nucleotide sequence SEQ ID NO.3;

[0069] (2) Insert SEQ ID NO.3 into the pLVX-IRES-ZsGreen1 vector, and then package the therapeutic virus in 293T cells to obtain the immune drug.

Embodiment 3

[0071] In this example, the type A drug provided in Example 2 was used to treat tumors in mice, and the therapeutic effect was observed. The specific operation steps are as follows:

[0072] The MC38 cells used in this example come from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; cultured at 37°C, 5% CO 2 In a humidified atmosphere, the medium was RPMI-1640 medium (Thermo Fisher, USA) supplemented with 10% fetal bovine serum.

[0073] (1) Three weeks in advance, immunize 6 five-week-old, 20-g C57 mice (purchased from Beijing Huafukang Company) with A blood group antigen, and immunize once a week after the first immunization; under SPF conditions , mice were housed in cages, and each cage contained up to five mice at the Experimental Animal Center of Southern Medical University.

[0074] (2) Inoculate MC38 colorectal cancer cell line (2×10 5 / only) in the subcutaneous part of the mouse;

[0075] (3) After five days,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a novel immune medicine for treating solid tumors, the immune medicine comprises a virus expression vector for simultaneously expressing a Fut1 gene and an ABO blood group gene,and the ABO blood group gene comprises an N-acetylgalactosamine transferase gene and / or a galactosyl transferase gene. According to the immune drug, a human ABO blood group gene is cloned to a medical drug-grade lentiviral vector; co-expression with a Fut1 gene is carried out; the prepared medical drug-grade lentiviral drug is injected into a tumor part through a solid tumor local injection method; according to the present invention, the target gene sequence is permanently translated in tumor cells, such that a large amount of the blood group antigen is expressed on the surface of the tumor cell membrane, and the blood group antigen can be recognized by the corresponding blood group antibody existing in serum so as to activate the complement so as to kill the tumor cells and achieve the tumor reduction purpose;

Description

technical field [0001] The invention belongs to the field of immunotherapy, and in particular relates to an immunomedicine, in particular to a novel immunomedicine for treating solid tumors. Background technique [0002] ABO blood group antigens are glycoproteins and glycolipids on the surface of red blood cell membranes catalyzed by specific glycosyltransferases encoded by ABO blood group antigen genes. Three alleles form four main blood types, namely A type, B type, Type AB and Type O. Blood group antigens exist in three forms: free oligosaccharides, protein-bound and lipid-bound. The first two can be secreted into various body fluids, while most blood group antigens bound to cell membranes are lipid-bound. The lipid-binding blood group antigen with immune activity is located on the outer membrane of the cell membrane, and can be expressed not only by red blood cells, but also widely expressed in other cells and tissues, such as digestive tract epithelial cells, etc. Ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K39/00A61P35/00
CPCA61K9/0019A61K39/0005A61P35/00A61K2039/5256A61K2039/53
Inventor 王磊罗琼
Owner 王磊
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com